Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway

The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF alpha signaling path-way. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as "TRAF2 truncated" or "TRAF2TR" and a TRAF2 expression constru...

Full description

Saved in:
Bibliographic Details
Main Authors SEARFOSS, III GEORGE H, GUO KUN, PAGNONI MARCO F, CLARK KENNETH L, IVASHCHENKO YURI D
Format Patent
LanguageEnglish
Published 14.02.2006
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF alpha signaling path-way. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as "TRAF2 truncated" or "TRAF2TR" and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as "TRAF2 truncated-deleted" or "TRAF2TD". Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF alpha signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF alpha binding.
Bibliography:Application Number: US20020018030